Amendment to the Claims:

The listing of claim will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-51 (canceled)

Claim 52 (canceled)

Claim 53 (withdrawn): A pharmaceutical composition, according to claim 52, comprising bromocriptine as the drug compound.

Claim 54 (canceled)

Claim 55 (withdrawn): A pharmaceutical composition, according to claim 52, comprising somatostatin as the drug compound.

Claim 56 (currently amended): ~~A~~ The pharmaceutical composition, according to claim ~~52~~ 74, ~~comprising~~ wherein the hydrophilic or lipophilic drug is selected from bromocriptine, octreotide, or an acid addition salt thereof[[,]]. ~~as the drug compound.~~

Claim 57 (withdrawn): A process, for the preparation of the pharmaceutical composition of claim 52, which comprises combining a polymer which is off-white to white in color, and which polymer contains one or more metals in cationic form, with the drug compound to form an implantate or a microparticle.

Claim 58 (currently amended): ~~A~~ The pharmaceutical composition, according to claim ~~52~~ 74, wherein the off-white to white color is further defined by the requirements of the colour strengths of reference solutions B_2-B_9 of the brown colour test of the European Pharmacopeia, 2nd Edition (1980) part I, Section V, 6.2.

Claim 59 (canceled)

Claim 60 (currently amended): ~~A~~ The pharmaceutical composition according to claim ~~59~~ 74 wherein the polylactide polymer is a polylactide co-glycolide polymer.

Claim 61 (canceled)

Claim 62 (canceled)

Claim 63 (canceled)

Claim 64 (currently amended): ~~A~~ The pharmaceutical composition according to claim ~~62~~ 60 wherein the polylactide co-glycolide polymer is a polylactide co-glycolide having a mean molecular weight (M_w) of from ~~25~~10,000 to ~~100~~200,000. ~~and a polydispersity ($Mw/_{Mn}$) of from 1.2 to 3.0.~~

Claim 65 (canceled)

Claim 66 (currently amended): ~~A~~ The pharmaceutical composition according to claim ~~65~~ 60 wherein the ~~linear~~ polylactide co-glycolide polymer has a lactidal glycolide molar ratio of 100-25/0-75.

Claim 67 (currently amended): ~~A~~ The pharmaceutical composition according to claim ~~65~~ 60 wherein the ~~linear~~ polylactide co-glycolide polymer has a lactidal glycolide molar ratio of 75-25/25-75.

Claim 68 (currently amended): ~~A~~ The pharmaceutical composition according to claim ~~65~~ 60 wherein the ~~linear~~ polylactide co-glycolide polymer has a lactidal glycolide molar ratio of 60-40/40-60.

Claim 69 (canceled)

Claim 70 (canceled)

Claim 71 (canceled)

Claim 72 (canceled)

Claim 73 (canceled)

Claim 74 (new): A pharmaceutical composition comprising (a) polylactide polymer in a purified state wherein the polylactide polymer in a purified state is an ester of a polyol containing at least three hydroxyl groups and is off-white to white in color, and wherein the polylactide in a purified state contains one or more metals in cationic form wherein the one or more metals have a concentration up to 10 ppm; and (b) a hydrophilic or lipophilic drug.

Claim 75 (new): The pharmaceutical composition according to claim 74 wherein the polyol is glucose.

Claim 76 (new): The pharmaceutical composition according to claim 74 wherein the pharmaceutical composition is an implant.

Claim 77 (new): The pharmaceutical composition according to claim 74 wherein the pharmaceutical composition is a microparticle.

Claim 78 (new): The pharmaceutical composition according to claim 60 wherein the polylactide co-glycolide polymer is a polylactide co-glycolide having a mean molecular weight (M_w) of from 25,000 to 100,000.

Claim 79 (new): The pharmaceutical composition according to claim 60 wherein the polylactide co-glycolide polymer is a polylactide co-glycolide having a mean molecular weight (M_w) of from 35,000 to 60,000.

Claim 80 (new): The pharmaceutical composition according to claim 74 wherein the polylactide has a polydispersity M_w/M_n of from 1.7 to 3.0.

Claim 81 (new): The pharmaceutical composition according to claim 74 wherein the polylactide has a polydispersity M_w/M_n of from 20 to 2.5.

Claim 82 (new): The pharmaceutical composition according to claim 74, wherein the polylactide further comprises of:

a) monomer in a content of at most 1% by weight of polylactide;
b) water in a content of at most 1% by weight of polylactide;
c) ash in a content of at most 0.1% by weight of polylactide;

d) organic solvent in a content of at most 1% by weight of polylactide;

e) ethyl hexanoate in a content of at most 0.5% by weight of polylactide; and

f) an acid number up to 10.